<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-0099</journal-id>
<journal-title><![CDATA[Cirujano general]]></journal-title>
<abbrev-journal-title><![CDATA[Cir. gen]]></abbrev-journal-title>
<issn>1405-0099</issn>
<publisher>
<publisher-name><![CDATA[Asociación Mexicana de Cirugía General A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-00992021000100023</article-id>
<article-id pub-id-type="doi">10.35366/103910</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Resultados de la ablación por radiofrecuencia en el tratamiento de carcinoma hepatocelular en Veracruz, México]]></article-title>
<article-title xml:lang="en"><![CDATA[Radiofrequency ablation results in hepatocellular carcinoma treatment in Veracruz, Mexico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Mier]]></surname>
<given-names><![CDATA[Gustavo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Escobar-Ríos]]></surname>
<given-names><![CDATA[Alma Yrani]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esquivel-Torres]]></surname>
<given-names><![CDATA[Sergio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casanova-Sánchez]]></surname>
<given-names><![CDATA[Iván Eliud]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramírez-Sánchez]]></surname>
<given-names><![CDATA[Alonso Heriberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad Médica de Alta Especialidad (UMAE) No. 189 &#8220;Adolfo Ruíz Cortines&#8221; Departamento de Investigación]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Alta Especialidad de Veracruz Servicios de Salud de Veracruz Departamento de Cirugía Oncológica]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto Nacional de Ciencias Médicas y Nutrición &#8220;Salvador Zubirán&#8221; División de Radiología Intervencionista Departamento de Radiología e Imagen Molecular]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Mexicano del Seguro Social Unidad Médica de Alta Especialidad (UMAE) No. 189 &#8220;Adolfo Ruíz Cortines&#8221; Departamento de Cirugía General]]></institution>
<addr-line><![CDATA[Veracruz ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2021</year>
</pub-date>
<volume>43</volume>
<numero>1</numero>
<fpage>23</fpage>
<lpage>29</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-00992021000100023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-00992021000100023&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-00992021000100023&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  El carcinoma hepatocelular es el tumor primario hepático maligno más frecuente. Sólo 15% de los pacientes será sometido a resección quirúrgica o trasplante, por lo que la ablación local es un tratamiento alternativo con ventajas.  Objetivo:  Evaluar la eficacia de la ablación por radiofrecuencia en nuestra población.  Material y métodos:  Estudio retrospectivo de pacientes con carcinoma hepatocelular sometidos a ablación por radiofrecuencia; se investigaron variables sociodemográficas, del tumor, estadio (Child-Pugh, OKUDA, BCLC, CLIP, MELD y ALBI), uso de sorafenib y supervivencia.  Resultados:  Se analizaron 16 pacientes (edad media 71.25 años) con patología concomitante en 87.5%. El 62.5% de los pacientes padeció cirrosis, 56.3% Child-Pugh A y 6.3% B. El 62.5% fueron OKUDA I, 37.5% estadio BCLC A, 56.3% BCLC B y 6.3 % BCLC C; 56.3% se estadificó CLIP 0, MELD 8.44 ± 2.15 y ALBI -2.54 ± 0.42. El tamaño tumoral fue 5.81 ± 2.81 cm y sorafenib en 25%. La supervivencia media fue 37.7 meses, supervivencia al año 58.5% y a cinco años 23.4%. El índice de masa corporal se asocia a baja supervivencia (p = 0.031).  Conclusión:  Nuestro estudio indica que la ablación por radiofrecuencia se usa en pacientes con carcinoma hepatocelular en estadios variados y en ocasiones en tumores mayores a 5 cm, haciendo que la supervivencia sea menor a otros estudios.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  Hepatocellular carcinoma (HCC) is the most frequent malignant primary liver tumor. Only 15% of patients will undergo surgical resection or transplantation, thus local ablation is an important treatment with many advantages.  Objective:  To evaluate the effectiveness of radiofrequency ablation in our population.  Material and methods:  Retrospective study of patients with hepatocellular carcinoma undergoing radiofrequency ablation, analyzing sociodemographic variables, tumor relate, stage (Child-Pugh, OKUDA, BCLC, CLIP, MELD and ALBI), use of sorafenib and survival.  Results:  Sixteen patients (average age 71.25 years) with concomitant pathology in 87.5%, were analyzed. 62.5% of the patients suffered cirrhosis, 56.3% Child-Pugh A and 6.3% B. 62.5% of patients were OKUDA I. 37.5% with BCLC A, 56.3% BCLC B and 6.3% BCLC C. 56.3% were CLIP 0. Average MELD 8.44 ± 2.15 and average ALBI -2.54 ± 0.42. Tumor size was 5.81 ± 2.81 cm and use of sorafenib in 25%. Average survival was 37.76 months, survival rate 58.5% at one year and 23.4% at five. Low body mass index was associated with low survival (p = 0.031).  Conclusion:  Our study indicates that radiofrequency ablation is used in patients with hepatocellular carcinoma in various stages and sometimes in tumors &gt; 5 cm, making survival shorter than other studies.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Carcinoma hepatocelular]]></kwd>
<kwd lng="es"><![CDATA[ablación por radiofrecuencia]]></kwd>
<kwd lng="es"><![CDATA[supervivencia]]></kwd>
<kwd lng="es"><![CDATA[índice de masa corporal]]></kwd>
<kwd lng="en"><![CDATA[Hepatocellular carcinoma]]></kwd>
<kwd lng="en"><![CDATA[radiofrequency ablation]]></kwd>
<kwd lng="en"><![CDATA[survival]]></kwd>
<kwd lng="en"><![CDATA[body mass index]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wallace]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Preen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jeffrey]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The evolving epidemiology of hepatocellular carcinoma: a global perspective]]></article-title>
<source><![CDATA[Expert Rev Gastroenterol Hepatol]]></source>
<year>2015</year>
<volume>9</volume>
<page-range>765-79</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Center]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global cancer statistics]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2011</year>
<volume>61</volume>
<page-range>69-90</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verslype]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rosmorduc]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Rougier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up]]></article-title>
<source><![CDATA[Ann Oncol]]></source>
<year>2012</year>
<volume>23</volume>
<page-range>vii43-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[WS]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cryosurgery as a treatment for advanced stage hepatocellular carcinoma: results, complications, and alcohol ablation]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1998</year>
<volume>82</volume>
<page-range>1268-78</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ning Chong]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[San Lai]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Treatment strategy for recurrent hepatocellular carcinoma]]></source>
<year>2012</year>
<page-range>123-6</page-range><publisher-loc><![CDATA[Hong Kong ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wai Kit Ip]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Fong]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatocellular carcinoma: current surgical management]]></article-title>
<source><![CDATA[Gastroenterology]]></source>
<year>2004</year>
<volume>127</volume>
<page-range>S248-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kudo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Osaki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score)]]></article-title>
<source><![CDATA[J Gastroenterol]]></source>
<year>2003</year>
<volume>38</volume>
<page-range>207-15</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adhoute]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Pénaranda]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Raoul]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort]]></article-title>
<source><![CDATA[World J Gastroenterol]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>2545-55</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamath]]></surname>
<given-names><![CDATA[PS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The model for end-stage liver disease (MELD)]]></article-title>
<source><![CDATA[Hepatology]]></source>
<year>2007</year>
<volume>45</volume>
<page-range>797-805</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Albumin-bilirubin (ALBI) score at admission predicts possible outcomes in patients with acute-on-chronic liver failure]]></article-title>
<source><![CDATA[Medicine]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lencioni]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cioni]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Crocetti]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation]]></article-title>
<source><![CDATA[Radiology]]></source>
<year>2005</year>
<volume>234</volume>
<page-range>961-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[HK]]></given-names>
</name>
<name>
<surname><![CDATA[Rhim]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma: analysis of prognostic factors]]></article-title>
<source><![CDATA[J Hepatol]]></source>
<year>2013</year>
<volume>58</volume>
<page-range>89-97</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nouso]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kariyama]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of radiofrequency ablation for the treatment of intermediate-stage hepatocellular carcinoma]]></article-title>
<source><![CDATA[J Gastroenterol Hepatol]]></source>
<year>2017</year>
<volume>32</volume>
<page-range>695-700</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Chok]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm]]></article-title>
<source><![CDATA[HPB (Oxford)]]></source>
<year>2015</year>
<volume>17</volume>
<page-range>226-31</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Percutaneous thermal ablation of medium and large hepatocellular carcinoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2009</year>
<volume>115</volume>
<page-range>1914-23</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mier]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical images in gastroenterology. Radiofrequency ablation of the right lobe hepatocarcinoma]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2006</year>
<volume>71</volume>
<page-range>508</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Negative impact of low body mass index on liver cirrhosis patients with hepatocellular carcinoma]]></article-title>
<source><![CDATA[World J Surg Oncol]]></source>
<year>2015</year>
<volume>13</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Body mass index and waistline are predictors of survival for hepatocellular carcinoma after hepatectomy]]></article-title>
<source><![CDATA[Med Sci Monit]]></source>
<year>2015</year>
<volume>21</volume>
<page-range>2203-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feng]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Du]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study]]></article-title>
<source><![CDATA[Am J Gastroenterol]]></source>
<year>2014</year>
<volume>109</volume>
<page-range>1891-5</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gong]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Qin]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hou]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation]]></article-title>
<source><![CDATA[Oncol Lett]]></source>
<year>2017</year>
<volume>14</volume>
<page-range>7045-8</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mondragón-Sánchez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Murrieta-González]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez-González]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ablation of malignant liver tumors with radiofre- quency. A series of cases in Mexico]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2009</year>
<volume>74</volume>
<page-range>212-6</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ladron de Guevara]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas-Macuil]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchez-Chavez]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatocellular carcinoma: epidemiological profile from a cohort of federal employees in Mexico]]></article-title>
<source><![CDATA[Ann Hepatol]]></source>
<year>2009</year>
<volume>8</volume>
<page-range>212-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cisneros Garza]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Characterization of hepatocellular carcinoma in Mexico]]></article-title>
<source><![CDATA[Rev Gastroenterol Mex]]></source>
<year>2018</year>
<volume>83</volume>
<page-range>1-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
